[1] 戚庆炜,郝娜,周京,等.羊水间期细胞荧光原位杂交检测残余风险评估:6125例产前细胞遗传学诊断回顾性分析[J].生殖医学杂志, 2015, 24(6):429-435. [2] Yang S F, Lv J Y, Si Y M, et al. Diagnostic differences between patients opting for non-invasive prenatal testing and patients having traditional prenatal diagnosis[J]. Int J Clin Exp Pathol, 2018, 11(5):2831-2838. [3] Xiao H, Yang Y L, Zhang C Y, et al. Karyotype analysis with amniotic fluid in 12365 pregnant women with indications for genetic amniocentesis and strategies of prenatal diagnosis[J]. J Obstet Gynaecol, 2016, 36(3):293-296. [4] ISCN. 2016, An International system for human cytogenomic nomenclature[S]. Switzerland:KARGER, 2016. [5] Li C, Chen B, Zheng J, et al. Prenatal diagnosis of BACs-on-beads assay in 3647 cases of amniotic fluid cells[J]. Reprod Sci, 2019, 26(7):1005-1012. [6] Zheng J, Yang X, Lu H, et al. Prenatal diagnosis of sex chromosome mosaicism with two marker chromosomes in three cell lines and a review of the literature[J]. Mol Med Rep, 2019, 19(3):1791-1796. [7] Ketheeswaran S, Alsbjerg B, Christensen P, et al. 45,X/46,XY mosaicism and normozoospermia in a patient with male phenotype[J]. Case Rep Med, 2019, 2019(1):1-5. [8] Srebniak M I, Joosten M, Knapen M, et al. Frequency of submicroscopic chromosomal aberrations in pregnancies without increased risk for structural chromosomal aberrations:systematic review and meta-analysis[J]. Ultrasound Obstet Gynecol, 2018, 51(4):445-452. [9] Koumbaris G, Kypri E, Tsangaras K, et al. Cell-free DNA analysis of targeted genomic regions in maternal plasma for non-invasive prenatal testing of trisomy 21, trisomy 18, trisomy 13, and fetal sex[J]. Clin Chem, 2016, 62(6):848-855. [10] Committee on G, the Society for Maternal-Fetal M. Committee opinion No.682:microarrays and next-generation sequencing technology:the use of advanced genetic diagnostic tools in obstetrics and gynecology[J]. Obstet Gynecol, 2016, 128(6):e262-e268. [11] Cheng Y, Leung W C, Leung T Y, et al. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome:a prospective study[J]. BJOG, 2018, 125(4):451-459. [12] Williams J, Rad S, Beauchamp S, et al. Utilization of noninvasive prenatal testing:impact on referrals for diagnostic testing[J]. Am J Obstet Gynecol, 2015, 213(1):102 e1-6. [13] Cheng Y, Leung W C, Leung T Y, et al. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome:a prospective study[J]. BJOG, 2018, 125(4):451-459. [14] Korpi-Steiner N, Chiu R W K, Chandrasekharan S, et al. Emerging considerations for noninvasive prenatal testing[J]. Clin Chem, 2017, 63(5):946-953. |